Typically when an anchor patent is due to expire and during it’s lifetime, a number of supporting patent applications are filed. For us this meant extending to (a) other conditions / therapies and (b) combinations of either therapeutic agents or different wavelengths; whilst Always including the core technology.
This is standard practice – for example, with Pfizer’s Viagra or Astra-Zenica’s Tenormin. Whilst these are examples of therapeutic compounds the principle is the same – you seek to ink up with other therapeutics to extend patent life or develop new formulations.
We have done exactly this; By filing a tranche of mixed wavelength patent applications this can be considered as analogous to “different formulations” patent applications; by fusing with Samaritan we cover “combined formulation” patents.
In addition as 1072nm is in the form of a medical device we have the added protection layer of registered designs which is not afforded to molecules / therapeutics or compounds.